Vididencel highlighted in Cancer Center Amsterdam Annual Report 2022

Amsterdam, The Netherlands

Mendus’ pipeline program vividencel and the currently active ADVANCE II clinical study were recently highlighted in the Annual Report 2022 of our long-term collaboration partner, the Cancer Center Amsterdam – part of Amsterdam UMC. It’s an honor to be featured as one of the lighthouse projects of 2022 by one of the world’s leading cancer organizations. The article provides valuable insights on the remarkable journey of a novel vaccine candidate from bench to bedside through the lens of the study’s Primary Investigator, Prof. Arjan van de Loosdrecht.

To read the report (In English), click here.


Keep reading

Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue